Q-omics provides the consensus-scored PSORS1C3 profile across patient tissues and cancer cell-line models. PSORS1C3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PSORS1C3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PSORS1C3 RNA expression shows 11,555 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, KIRC, and KIRP as cancer lineages where PSORS1C3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSORS1C3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSORS1C3 survival associations across molecular data types. PSORS1C3 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSORS1C3 RNA expression–survival associations across cancer types. High PSORS1C3 expression shows favorable associations in BLCA, UCEC, BRCA, READ, UCS and THCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PSORS1C3 RNA expression.
This table summarizes PSORS1C3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PSORS1C3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSORS1C3 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, LIHC, STAD and CHOL. The KIRC box plot shows higher PSORS1C3 RNA expression in tumor versus normal tissue (log2 FC = +2.087, t-test p < 0.001).
This table shows molecular features associated with PSORS1C3 in patient tissues and cancer cell lines. In patient samples, PSORS1C3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
